Clinical trials
Breast Cancer (Triple Negative Breast Cancer (TNBC)) clinical trials
Below are recruiting breast cancer (triple negative breast cancer (tnbc)) clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT07439458Recruiting
Exercise effects on tumor cells in breast cancer survivors
This trial tests whether different types and intensities of exercise can change tumor-related cells in survivors of triple-negative breast cancer. It may help understand how exercise could improve long-term outcomes.
Riga, Dzirciema Street 16Ages 35 years+ - NCT07540533RecruitingPhase 2
Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Zhengzhou, HenanAges 18 years+ - NCT07739485RecruitingPhase 1/Phase 2
Oral paclitaxel before surgery for triple-negative breast cancer
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
Guiyang, GuizhouAges 18–70 - NCT07297667RecruitingPhase 1
CAR T-cell therapy for GPNMB-positive solid tumours
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Calgary, AlbertaAges 15 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Margate, FloridaAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Birmingham, AlabamaAges 18 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT04159818RecruitingPhase 2
Adding immune treatments to improve checkpoint drug response in TNBC
This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.
AmsterdamAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT04427293RecruitingPhase 1
Testing lenvatinib and pembrolizumab before breast cancer surgery
This early-phase trial tests whether lenvatinib plus pembrolizumab given before surgery can help treat early-stage triple-negative breast cancer. If you qualify, you would receive study medicines before your planned operation to remove the tumor and nearby lymph nodes.
Chicago, IllinoisAges 18 years+ - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer (triple negative breast cancer (tnbc))?
- Yes. Clin2 currently lists 254 recruiting breast cancer (triple negative breast cancer (tnbc)) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer (triple negative breast cancer (tnbc)) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer (triple negative breast cancer (tnbc)) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.